These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 10875257

  • 1. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY, Peehl DM, Navone NM, Feldman D.
    Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
    [Abstract] [Full Text] [Related]

  • 2. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S, Agoulnik IU, Weigel NL.
    Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350
    [Abstract] [Full Text] [Related]

  • 4. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan 01; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 5. Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1999 Mar 01; 140(3):1205-12. PubMed ID: 10067845
    [Abstract] [Full Text] [Related]

  • 6. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 01; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
    Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, Taguchi H, Koeffler HP.
    Cancer Res; 2005 Jun 01; 65(11):4762-8. PubMed ID: 15930295
    [Abstract] [Full Text] [Related]

  • 9. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M.
    Cancer Res; 2003 Sep 01; 63(17):5622-8. PubMed ID: 14500404
    [Abstract] [Full Text] [Related]

  • 10. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells.
    Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO.
    Prostate; 2008 May 15; 68(7):773-83. PubMed ID: 18247401
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 15; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 13. 5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
    Lou YR, Nazarova N, Talonpoika R, Tuohimaa P.
    Prostate; 2005 May 15; 63(3):222-30. PubMed ID: 15538745
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells.
    Bao BY, Hu YC, Ting HJ, Lee YF.
    Oncogene; 2004 Apr 22; 23(19):3350-60. PubMed ID: 15048085
    [Abstract] [Full Text] [Related]

  • 16. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
    Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL.
    Mol Cell Endocrinol; 2002 Jan 15; 186(1):69-79. PubMed ID: 11850123
    [Abstract] [Full Text] [Related]

  • 17. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3.
    Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P.
    Cancer Res; 1992 Feb 01; 52(3):515-20. PubMed ID: 1370648
    [Abstract] [Full Text] [Related]

  • 18. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G.
    Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276
    [Abstract] [Full Text] [Related]

  • 19. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.
    Cancer Res; 2004 Oct 01; 64(19):7156-68. PubMed ID: 15466214
    [Abstract] [Full Text] [Related]

  • 20. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 01; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.